Factive Related Published Studies
Well-designed clinical trials related to Factive (Gemifloxacin)
Clinical effectiveness and safety of gemifloxacin versus cefpodoxime in acute exacerbation of chronic bronchitis: A randomized, controlled trial. [2011.02]
Bioequivalence evaluation of 320 mg gemifloxacin tablets in healthy volunteers. [2007.11]
Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. [2004.08]
A randomized, double-blind study comparing 5 days oral gemifloxacin with 7 days oral levofloxacin in patients with acute exacerbation of chronic bronchitis. [2004.08]
Serum bactericidal activity of gemifloxacin versus clarithromycin against Streptococcus pneumoniae with different susceptibility to quinolones. [2004.02]
Oral gemifloxacin once daily for 5 days compared with sequential therapy with i.v. ceftriaxone/oral cefuroxime (maximum of 10 days) in the treatment of hospitalized patients with acute exacerbations of chronic bronchitis. [2003.03]
Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability. [2002.11]
Cost-effectiveness of gemifloxacin: results from the GLOBE study. [2002.07.15]
Short treatment durations for acute bacterial rhinosinusitis: Five days of gemifloxacin versus 7 days of gemifloxacin. [2002.07]
A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. [2002.04]
Urinary excretion and bactericidal activities of gemifloxacin and ofloxacin after a single oral dose in healthy volunteers. [2001.12]
Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers. [2001.09]
Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin. [2001.07]
Efficacy of gemifloxacin in acute exacerbations of chronic bronchitis: a randomised, double-blind comparison with trovafloxacin. [2001.06]
Impact of gemifloxacin on the normal human intestinal microflora. [2001.02]
Effects of single oral doses of gemifloxacin (320 milligrams) versus trovafloxacin (200 milligrams) on fecal flora in healthy volunteers. [2001.02]
Multiple-dose pharmacokinetics and tolerability of gemifloxacin administered orally to healthy volunteers. [2001.02]
The effect of food on the bioavailability of oral gemifloxacin in healthy volunteers. [2000.09]
Gemifloxacin versus amoxicillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis. The 070 Clinical Study group. [2000.08]
The effect of ferrous sulphate and sucralfate on the bioavailability of oral gemifloxacin in healthy volunteers. [2000.08]
Evaluation of phototoxic potential of gemifloxacin in healthy volunteers compared with ciprofloxacin. [1999.11]
Effect of omeprazole on the pharmacokinetics of oral gemifloxacin in healthy volunteers. [1999.11]
Lack of effect of gemifloxacin on the steady-state pharmacodynamics of warfarin in healthy volunteers. [1999.11]
Well-designed clinical trials possibly related to Factive (Gemifloxacin)
Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials. [2008.12.02]
Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials. [2008.12.02]
Clinical characteristics and response to newer quinolones in Legionella pneumonia: a report of 28 cases. [2003.10]
Time course of recovery of health status following an infective exacerbation of chronic bronchitis. [2003.07]
Other research related to Factive (Gemifloxacin)
Clarithromycin vs. Gemifloxacin in Quadruple Therapy Regimens for Empiric Primary
Treatment of Helicobacter pylori Infection: A Randomized Clinical Trial. [2015]
The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus
azithromycin as treatment of uncomplicated gonorrhea. [2014]
Twenty-eight days repeated oral dose toxicity study of gemifloxacin in Wistar albino rats. [2010.11]
Convulsant activity and pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of gemifloxacin in rats. [2010.03]
[Gemifloxacin for the treatment of uncomplicated urinary infections (acute cystitis)] [2009.12]
A probable association of acute dystonia with gemifloxacin administration. [2009.12]
Competitive inhibition of renal tubular secretion of gemifloxacin by probenecid. [2009.09]
Gemifloxacin-associated neurotoxicity presenting as encephalopathy. [2009.04]
Gemifloxacin use in the treatment of acute bacterial exacerbation of chronic bronchitis. [2009]
Role of gemifloxacin in community-acquired pneumonia. [2008.08]
Gemifloxacin for community-acquired pneumonia. [2008.05]
Role of gemifloxacin in the management of community-acquired lower respiratory tract infections. [2008.04]
Cost-effectiveness of oral gemifloxacin versus intravenous ceftriaxone followed by oral cefuroxime with/without a macrolide for the treatment of hospitalized patients with community-acquired pneumonia. [2008.01]
Cost-effectiveness of oral gemifloxacin versus intravenous ceftriaxone followed by oral cefuroxime with/without a macrolide for the treatment of hospitalized patients with community-acquired pneumonia. [2007.09.20]
Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study. [2007.07]
Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study. [2007.05.30]
Short-course therapy of gemifloxacin effective against pneumococcal pneumonia in mice. [2006.12]
Cutaneous adverse events and gemifloxacin: observations from the clinical trial program. [2006.02]
Gemifloxacin for the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety. [2005.05]
In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point. [2005.02]
Gemifloxacin: a new, potent fluoroquinolone for the therapy of lower respiratory tract infections. [2004.12]
Concentrations of gemifloxacin at the target site in healthy volunteers after a single oral dose. [2004.11]
Gemifloxacin: a new fluoroquinolone approved for treatment of respiratory infections. [2004.07]
Antimicrobial selection for community-acquired lower respiratory tract infections in the 21st century: a review of gemifloxacin. [2004.06]
Gemifloxacin: a new fluoroquinolone. [2004.05]
A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context. [2004.05]
Activity of gemifloxacin against Streptococcus pneumoniae and Haemophilus influenzae. [2004.02]
In vitro susceptibility of 4903 bacterial isolates to gemifloxacin--an advanced fluoroquinolone. [2003.08]
Effect of calcium carbonate on bioavailability of orally administered gemifloxacin. [2003.07]
Efficacy and pharmacodynamics of gemifloxacin versus levofloxacin in guinea pig pneumococcal pneumonia induced by strains with decreased ciprofloxacin susceptibility. [2003.06]
Gemifloxacin: effects of sub-inhibitory concentrations on various factors affecting bacterial virulence. [2003.04]
In vitro activity of gemifloxacin against recent clinical isolates of bacteria in Korea. [2002.12]
Effect of gemifloxacin on viability of Chlamydia pneumoniae (Chlamydophila pneumoniae) in an in vitro continuous infection model. [2002.05]
Gemifloxacin is efficacious against penicillin-resistant and quinolone-resistant pneumococci in experimental meningitis. [2002.05]
In vitro activity of gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia. [2001.08]
Efficacy and safety of gemifloxacin 320 mg once-daily for 7 days in the treatment of adult lower respiratory tract infections. [2001.07]
Antibacterial properties of gemifloxacin and trovafloxacin in urine ex vivo: phase I study. [2001.06]
Pharmacokinetics and tissue penetration of gemifloxacin following a single oral dose. [2001.04]
Gemifloxacin: survival of the fittest. [2000.07]
Development of gemifloxacin in vitro susceptibility test methods for gonococci including quality control guidelines. The Quality Control Study Group. [2000.07]
Pharmacokinetics and tolerability of gemifloxacin (SB-265805) after administration of single oral doses to healthy volunteers. [2000.06]
Gemifloxacin. [2000.05]
Comparative efficacy of gemifloxacin in experimental models of pyelonephritis and wound infection. [2000.04]
Gemifloxacin is effective in experimental pneumococcal meningitis. [2000.03]
Other possibly related research studies
Appropriate outpatient treatment of acute bacterial exacerbations of chronic bronchitis. [2005.07]
Antimicrobial treatment of lower respiratory tract infections in the hospital setting. [2005.07]
Guide to selection of fluoroquinolones in patients with lower respiratory tract infections. [2005]
Gateways to clinical trials. [2004.11]
[Clonal diversity and antimicrobial susceptibility of Acinetobacter baumannii isolated in Spain. A nationwide multicenter study: GEIH-Ab project (2000)] [2004.05]
Quinolone-resistant Haemophilus influenzae in a long-term care facility: clinical and molecular epidemiology. [2004.06.01]
Monotherapy versus dual therapy for community-acquired pneumonia in hospitalized patients. [2004.05.15]
New therapies for pneumococcal meningitis. [2004.04]
Pseudomonal infections in patients with COPD: epidemiology and management. [2003]
Short-course antimicrobial therapy of respiratory tract infections. [2003]
Treatment of bacterial skin and skin structure infections. [2003.08]
The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. [2003.08]
Telithromycin and quinupristin-dalfopristin resistance in clinical isolates of Streptococcus pyogenes: SMART Program 2001 Data. [2003.07]
Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. [2003.06]
Five-year analysis of Haemophilus influenzae isolates with reduced susceptibility to fluoroquinolones: prevalence results from the SENTRY antimicrobial surveillance program. [2003.05]
Maximizing efficacy and reducing the emergence of resistance. [2003.05]
In vitro antibacterial activity and pharmacodynamics of new quinolones. [2003.04]
Novel antibacterial agents for the treatment of serious Gram-positive infections. [2003.03]
In vitro and in vivo antibacterial activities of DW286, a new fluoronaphthyridone antibiotic. [2002.09]
Intra-abdominal anaerobic infections: bacteriology and therapeutic potential of newer antimicrobial carbapenem, fluoroquinolone, and desfluoroquinolone therapeutic agents. [2002.09.01]
In vitro activities of new quinolones against Brucella melitensis isolated in a tertiary-care hospital in Turkey. [2002.04]
Characterization of clinical Streptococcus pneumoniae strains from Germany with decreased susceptibility to fluoroquinolones. [2002.06]
Resistance among Streptococcus pneumoniae: Implications for drug selection. [2002.06.15]
[Flouroquinolones of the third and fourth generations] [2001.11]
A critical review of the fluoroquinolones: focus on respiratory infections. [2002]
Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections. [2001.10]
[Third and fourth generation fluoroquinolones] [2001.10]
Fluoroquinolone susceptibility, resistance, and pharmacodynamics versus clinical isolates of Streptococcus pneumoniae from Indiana. [2001.08]
Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. [2001]
Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy. [2001.09.15]
|